These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

774 related items for PubMed ID: 9345325

  • 1. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andras EJ, Asbell SO, Rotman M, Cox JD.
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [Abstract] [Full Text] [Related]

  • 2. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
    Komaki R, Scott CB, Sause WT, Johnson DH, Taylor SG, Lee JS, Emami B, Byhardt RW, Curran WJ, Dar AR, Cox JD.
    Int J Radiat Oncol Biol Phys; 1997 Oct 01; 39(3):537-44. PubMed ID: 9336129
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
    Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W.
    Int J Radiat Oncol Biol Phys; 2002 Jul 01; 53(3):548-57. PubMed ID: 12062596
    [Abstract] [Full Text] [Related]

  • 4. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
    Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C.
    Int J Radiat Oncol Biol Phys; 1998 Oct 01; 42(3):469-78. PubMed ID: 9806503
    [Abstract] [Full Text] [Related]

  • 5. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.
    Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P, Byhardt RW.
    Int J Radiat Oncol Biol Phys; 1997 Apr 01; 38(1):149-55. PubMed ID: 9212017
    [Abstract] [Full Text] [Related]

  • 6. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.
    Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ.
    J Clin Oncol; 1996 Apr 01; 14(4):1055-64. PubMed ID: 8648357
    [Abstract] [Full Text] [Related]

  • 7. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
    Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD.
    J Natl Cancer Inst; 2011 Oct 05; 103(19):1452-60. PubMed ID: 21903745
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW, Choi EK, Lee JS, Lee SD, Suh C, Kim SW, Kim WS, Ahn SD, Yi BY, Kim JH, Noh YJ, Kim SS, Koh Y, Kim DS, Kim WD.
    Int J Radiat Oncol Biol Phys; 2003 Jul 15; 56(4):996-1004. PubMed ID: 12829135
    [Abstract] [Full Text] [Related]

  • 9. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL.
    Hematol Oncol Clin North Am; 2004 Feb 15; 18(1):41-53. PubMed ID: 15005280
    [Abstract] [Full Text] [Related]

  • 10. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S.
    J Clin Oncol; 1996 Apr 15; 14(4):1065-70. PubMed ID: 8648358
    [Abstract] [Full Text] [Related]

  • 11. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B, Milicić B.
    Cancer; 2008 Feb 15; 112(4):876-84. PubMed ID: 18172901
    [Abstract] [Full Text] [Related]

  • 12. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
    Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G.
    Int J Radiat Oncol Biol Phys; 2001 May 01; 50(1):19-25. PubMed ID: 11316542
    [Abstract] [Full Text] [Related]

  • 13. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
    Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT.
    J Natl Cancer Inst; 1995 Feb 01; 87(3):198-205. PubMed ID: 7707407
    [Abstract] [Full Text] [Related]

  • 14. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R.
    Strahlenther Onkol; 2003 Dec 01; 179(12):823-31. PubMed ID: 14652671
    [Abstract] [Full Text] [Related]

  • 15. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
    Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M, Andras EJ.
    Int J Radiat Oncol Biol Phys; 1999 May 01; 44(2):327-31. PubMed ID: 10760427
    [Abstract] [Full Text] [Related]

  • 16. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15.
    Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RL, Coughlin C, Scarantino C, Rotman M, Emami B.
    Cancer; 1995 May 01; 75(9):2337-44. PubMed ID: 7712445
    [Abstract] [Full Text] [Related]

  • 17. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC, Herndon JE, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M.
    J Clin Oncol; 1998 Nov 01; 16(11):3528-36. PubMed ID: 9817271
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
    Park J, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim DH, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K.
    Lung Cancer; 2003 Nov 01; 42(2):227-35. PubMed ID: 14568691
    [Abstract] [Full Text] [Related]

  • 19. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M.
    Int J Radiat Oncol Biol Phys; 1996 May 01; 35(2):343-50. PubMed ID: 8635942
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients.
    Felip E, Del Campo JM, Bodi R, Vera R, Casado S, Rubio D.
    Am J Clin Oncol; 1997 Aug 01; 20(4):404-6. PubMed ID: 9256899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.